Washington Legal Foundation Turns CED Policy Into Patient Access Issue
This article was originally published in The Gray Sheet
Executive Summary
CMS' coverage-with-evidence-development (CED) policy puts Medicare patients at unnecessary risk by restricting access to needed therapies, according to the Washington Legal Foundation
You may also be interested in...
Trade Groups Vet CMS’ Coverage-With-Evidence Development Guidance
CMS' requirement that additional data be collected as a condition of expanded ICD coverage should not be repeated in future national coverage decisions, according to AdvaMed
CMS Issues “Coverage With Evidence Development” Draft Guidance
CMS' "coverage with evidence development" (CED) draft guidance appears to venture into FDA's traditional jurisdiction of evaluating safety and effectiveness
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.